参考文献/References:
[1].Moradi H,Streja E,Vaziri ND. ESRD-induced dyslipidemia-should management of lipid disorders differ in dialysis patients?[J].Semin Dial,2018,31(4):398-405.
[2].Almarzooq ZI,Bhatt DL. Are statins back for patients on hemodialysis?[J].Eur J Prev Cardiol,2021,28(8):834-837.
[3].Mathew RO,Rosenson RS,Lyubarova R,et al. Concepts and controversies: lipid management in patients with chronic kidney disea se[J]. Cardiovasc Drugs Ther,2021,35(3):479-489.
[4].Pennell P,Leclercq B,Delahunty MI,et al. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease[J]. Clin Nephrol,2006,66(5):336-347.
[5].Homma K,Homma Y,Shiina Y,et al. Skew of plasma low- and high-density lipoprotein distributions to less dense subfractions in normotriglyceridemic chronic kidney disease patients on maintenance hemodialysis treatment[J]. Nephron Clin Pract,2013,123(1-2):41-45.
[6].Wanner C,Krane V,Marz W,et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis[J]. N Engl J Med,2005,353(3):238-248.
[7].Fellstrom BC,Jardine AG,Schmieder RE,et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis[J]. N Engl J Med,2009,360(14):1395-1407.
[8].Baigent C,Landray MJ,Reith C,et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection):a randomised placebo-controlled trial[J]. Lancet,2011,377(9784):2181-2192.
[9]. Hamada C,Okuda M,Tomino Y. Pitavastatin compared with differential intervention trial by standard therapy on cardiovascular events in patients with dyslipidemia on chronic hemodialy sis (DIALYSIS):a randomized controlled trial[J]. Blood Purif,2023,52(5):483-492.
[10].Huang CC,Chan WL,Chen YC,et al. The beneficial effects of statins in patients undergoing hemodialysis[J]. Int J Cardiol,2013,168(4):4155-4159.
[11].Hu YN,Luo CY,Tsai MT,et al. Post-coronary artery bypass medications in dialysis patients:do we need to change strategies?[J].Thorac Cardiovasc Surg,2020,68(8):706-713.
[12]. M?rz W,Genser B,Drechsler C,et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis [J]. Clin J Am Soc Nephrol,2011,6(6):1316-1325.
[13]. Markossian T,Burge N,Ling B,et al.Controversies regarding lipid management and statin use for cardiovascular risk reduction in patients with CKD[J]. Am J Kidney Dis,2016,67(6):965-977.
[14].王增武,刘静,李建军,等.中国血脂管理指南（2023年）[J].中国循环杂志,2023,38(3):237-271.
[15].de Vriese AS. Should statins be banned from dialysis?[J].J Am Soc Nephrol,2017,28(6):1675-1676.
[16].Chen Z,Qureshi AR,Parini P,et al. Does statins promote vascular calcifification in chronic kidney disease?[J].Eur J Clin Invest,2017,47(2):137-148.
[17]. Healy A,Berus JM,Christensen JL,et al . Statins disrupt macrophage rac1 regulation leading to increased atherosclerotic plaque calcification[J]. Arterioscler Thromb Vasc Biol,2020,40(3):714-732.
[18]. Lomashvili KA,Manning KE,Weitzmann MN,et al. Persistence of vascular calcification after reversal of urem ia[J]. Am J Pathol,2017,187(2):332-338.
[19]. Ren SC,Mao N,Yi S,et al. Vascular calcification in chronic kidney disease :an update and perspective[J]. Aging Dis,2022,13(3):673-697.
[20]. Struijk DG. Failure of statins to improve outcomes in dialysis patients:does peritonitis modify the impact of lipids on cardiovascular events?[J].Can J Cardiol,2020,36(1):22-23.
[21]. Tu?ón J,Steg PG,Bhatt DL,et al.Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome:prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial [J]. Eur Heart J,2020,41(42):4114-4123.
相似文献/References:
[1]张琼月 甘华.血液透析患者发生心脏性猝死的易患因素[J].心血管病学进展,2020,(7):738.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.016]
ZHANG Qiongyue,GAN Hua.Risk Factors for Sudden Cardiac Death in Hemodialysis Patients[J].Advances in Cardiovascular Diseases,2020,(12):738.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.016]
[2]张海福 张邢炜.血液透析患者冠状动脉介入治疗术后双联抗血小板治疗的进展[J].心血管病学进展,2020,(12):1281.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.014]
ZHANG Haifu,ZHANG Xingwei.Dual Antiplatelet Therapy after Coronary Intervention in Hemodialysis Patients[J].Advances in Cardiovascular Diseases,2020,(12):1281.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.014]
[3]王亚辉 杨滨.血液透析对行经皮冠状动脉介入治疗的患者合用阿司匹林及氯吡格雷抗血小板聚集的影响[J].心血管病学进展,2021,(10):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
WANG YahuiYANG Bin.Effect of Hemodialysis on the Antiplatelet Aggregation of Patients Undergoing Percutaneous Coronary Intervention Combined with Aspirin and Clopidogrel[J].Advances in Cardiovascular Diseases,2021,(12):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
[4]于航天 赵妍 龚昂未 张帅丹 管成健 陈树晨 肖冰?/html>.血脂与心力衰竭风险的因果关系及冠状动脉疾病的中介作用：一项孟德尔随机化研究[J].心血管病学进展,2024,(1):91.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.022]
YU Hangtian,ZHAO Yan,GONG Angwei,et al.Causal Relationship Between Lipids and Heart Failure Risk and Mediating Effect of Coronary Artery Disease: a Mendelian Randomization Study[J].Advances in Cardiovascular Diseases,2024,(12):91.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.022]